NCT02104310

A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 7 Years
• Healthy volunteers: Not accepted

Summary

For most brain tumors, radiation treatment is guided by a Magnetic Resonance Imaging (MRI) scan. In this study, information from a special scan, called a Positron Emission Tomography/ Computed Tomography (PET/CT) scan using an amino acid called Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used. This type of scan has shown promise in being able to better distinguish tumor from normal brain tissue and may help to more accurately plan radiation treatment. This type of scan can also assist the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of this study is to compare the 18F-DOPA PET/CT scan with the MRI scan for identifying where the disease is that needs to be treated with radiation.

Conditions

• Malignant Glioma

Interventions

Type	Name	Description
DRUG	Fluorine-18-L-dihydroxyphenylalanine	5 millicuries ± 10%; Intravenous injection; 1 time

Timeline

• Start date: 2014-04-08
• Primary completion: 2021-03-26
• Completion: 2031-03-01
• First posted: 2014-04-04
• Last updated: 2026-04-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study